Eric Langer, DO
Endocrinology, Diabetes & Metabolism · Sterling Heights, MINPI 1720003718
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $158,563 of the $213,045 with a category attached, or 74.4%. 57 manufacturers reported payments, led by Novo Nordisk at 51.8% of the total. Among endocrinology, diabetes & metabolism clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,488 payments — averaging $143.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$110K
- Ascendis Pharma Endocrinology Inc$60K
- IBSA Pharma Inc.$10K
- Johnson & Johnson$8K
- Medtronic$7K
- Senseonics, Incorporated$2K
- plus $15K from 51 others
Across 19 payments — averaging $619.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$12K
What the payments were for
- Consulting fees$7,7004%
- Speaking & faculty fees$158,56374%
- Travel & lodging$19,7129%
- Food & beverage$26,51612%
- Education$5550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yorvipath$52,431
- RYBELSUS$38,090
- Ozempic$31,112
- Tresiba$30,289
- Tirosint$10,952
- INVOKANA$6,917
- Tirosint-SOL$5,252
- Xultophy 100/3.6$3,485
- Minimed 670G System$3,195
- Eversense$1,787
- MINIMED 780G$1,524
- Minimed 770G System$466
- Omnipod$435
- Accurian$172
- INTELLIS ADAPTIVESTIM$157
- TWIIST$145
- EVERSENSE E3 SMART TRANSMITTER KIT$142
- InPen$138
- INPEN SMART INSULIN DELIVERY SYSTEM$128
- TZIELD$128
How this compares
$213,045 in reported general payments places this provider in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 246 | $487,808 |
| OzempicSemaglutide | 235 | $407,952 |
| JardianceEmpagliflozin | 155 | $223,269 |
| Tresiba Flextouch U-200Insulin Degludec | 74 | $66,037 |
| FarxigaDapagliflozin Propanediol | 50 | $65,650 |
| ForteoTeriparatide | 14 | $61,562 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 31 | $47,605 |
| Victoza 3-PakLiraglutide | 24 | $46,006 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 26 | $43,686 |
| MounjaroTirzepatide | 27 | $38,606 |
| NovologInsulin Aspart | 105 | $37,610 |
| RybelsusSemaglutide | 15 | $35,354 |
| Humalog Kwikpen U-100Insulin Lispro | 64 | $29,072 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $28,995 |
| JanuviaSitagliptin Phosphate | 25 | $27,616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Forteo, Mounjaro, Humalog | $1,187 | $615,181355 claims |
| Novo NordiskOzempic, Novolog, Rybelsus, Fiasp | $110,259 | $497,062367 claims |
| Boehringer IngelheimJardiance | $507 | $223,269155 claims |
| AstraZenecaFarxiga | $854 | $65,65050 claims |
| MerckJanuvia | $319 | $27,61625 claims |
| AbbVieSynthroid | $816 | $27,576247 claims |
| Johnson & JohnsonInvokana | $7,508 | $25,98218 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $521 | $14,7711,189 claims |
| PfizerGenotropin | $51 | $12,51611 claims |
| IBSA Pharma Inc.Tirosint | $9,954 | $8,89838 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Sterling Heights
- Amy TobinSterling Heights$37K
- Nancy AndrewsSterling Heights$20K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Ashish VermaShelby Twp$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.